新型降糖药物Exenatide研究进展及前景展望  

The Research Actuality and Prospect on Exenatide,a Novel Therapy for Type 2 Diabetes

作　　者：龙娟[1] 刘志敏[1] 杨晓红[2] 

机构地区：[1]军事医学科学院生物工程研究所,北京100071 [2]西南大学园艺园林学院,重庆400716

出　　处：《生物技术通讯》2008年第2期286-289,共4页Letters in Biotechnology

摘　　要：Exenatide是胰高血糖素样肽-1(GLP-1)受体的一种激动剂,可模拟人体自身激素GLP-1的功能,具有促进胰腺β-细胞增殖、改善其功能,以及促进胰岛素分泌,增加机体对胰岛素的敏感性和延缓胃排空等作用,因而有着传统治疗糖尿病药物不可比拟的优点,近年来已经成为糖尿病治疗领域的研究热点,应用前景非常广阔。简要介绍了Exenatide的生物活性、作用机理和临床应用现状,并对Exenatide长效降糖方面的研究进行了展望。Exenatide is a receptor agonist of the insulinotropic gut hormone glucagon-like peptide 1 （GLP-1）,which acts like the naturally occurring hormone GLP-1 in vivo. Its glucoregulatory activities include enhancing glucose-dependent insulin synthesis from pancreatic β-cells, decreasing glucagon production, slowing gastric emptying time, and also it is thought to have beneficial effects on β-cell mass. Lately it has represented an attractive therapeutic principle for diabetes. In this article, its physiological functions, mechanism, status quo, as well as its potential evolution were briefly reviewed.

关 键 词：EXENATIDE 糖尿病 胰高血糖素样肽-1受体 

分 类 号：R587.1[医药卫生—内分泌]